Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Johnson & Johnson. A complete text table follows the diagram.
Innovative Medicine remained the earnings engine while MedTech added diversified but lower-margin growth
Swipe to explore
Segment cost pools are exact differences between reported segment sales and segment pretax income; unallocated expense is separately reported.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Innovative Medicine | 1 | $15.4B | Oncology, immunology and neuroscience; up 11% |
| MedTech | 1 | $8.6B | Cardiovascular, surgery, vision and orthopaedics; up 8% |
| Medicine segment pretax income | 2 | $5.3B | 34.5% segment margin |
| MedTech segment pretax income | 2 | $1.2B | 14.3% segment margin |
| Medicine costs & investment | 2 | $10.1B | Manufacturing, commercialization and R&D |
| MedTech costs & investment | 2 | $7.4B | Manufacturing, selling, R&D and separation costs |
| Segment pretax contribution | 3 | $6.6B | Before unallocated corporate items |
| Consolidated pretax income | 4 | $6.0B | 24.9% of sales |
| Unallocated expense | 4 | $566M | Interest, talc and corporate items |
| Net earnings | 5 | $5.2B | 21.8% net margin |
| Income tax | 5 | $755M | 12.6% effective rate |
| From | To | Value |
|---|---|---|
| Innovative Medicine | Medicine segment pretax income | $5.3B |
| Innovative Medicine | Medicine costs & investment | $10.1B |
| MedTech | MedTech segment pretax income | $1.2B |
| MedTech | MedTech costs & investment | $7.4B |
| Medicine segment pretax income | Segment pretax contribution | $5.3B |
| MedTech segment pretax income | Segment pretax contribution | $1.2B |
| Segment pretax contribution | Consolidated pretax income | $6.0B |
| Segment pretax contribution | Unallocated expense | $566M |
| Consolidated pretax income | Net earnings | $5.2B |
| Consolidated pretax income | Income tax | $755M |